|
Jul 25
|
We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn
|
|
Jun 14
|
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
|
|
May 14
|
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
|
|
May 8
|
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
|
|
May 5
|
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
|
May 3
|
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
|
|
May 3
|
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
|
|
May 3
|
Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 2
|
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
|
|
Apr 26
|
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 25
|
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
|
Apr 25
|
20 Counties with the Highest Cancer Rates in the US
|
|
Apr 25
|
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
|
|
Apr 8
|
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
|
|
Mar 8
|
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
|
|
Mar 5
|
Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)
|
|
Jan 9
|
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
|
|
Jan 9
|
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Jan 9
|
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
|